Pfizer stops one of two Phase 3 trials for sickle cell drug, still plans to seek approval in 2026
26 Mar 2024
Phase 3AcquisitionPhase 2Clinical Trial Failure
Pfizer terminated one of two late-stage trials for a sickle cell treatment candidate from its $5.4 billion acquisition of Global Blood Therapeutics in 2022.
The pharma giant is still running a second Phase 3 for the drug, known as inclacumab, a spokesperson confirmed Tuesday to Endpoints News.
A Monday update to the federal clinical trials database shows that Pfizer ended a Phase 3 of inclacumab due to “poor accrual and associated [recruitment] challenges.” The study enrolled 72 people out of an originally planned 280, according to clinicaltrials.gov.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.